Keywords:
COVID-19, SARS-CoV-2, хроническая болезнь почек, диализ, трансплантация почки.References
Beigel, J.H., Tomashek, K.M., Dodd, L.E., et al. Remdesivir for the Treatment of COVID-19 — Final Report. N. Engl. J. Med., 2020; 383: 1813–1826.
Chan, L., Chaudhary, K., Saha, A., et al. AKI in Hospitalized Patients with COVID-19. J. Am. Soc. Nephrol., 2021; 32: 151–160.
Fihn, S.D., Jacobs, E.A., Kim, H.S., Perencevich, E.N. JAMA Network Open—The Year in Review, 2024. JAMA Netw Open, 2025; 8(3): e257199.
Forman, K.J., Marquez, N., Dolgert, A., et al. Forecasting Life Expectancy, Years of Life Lost, and All-Cause and Cause-Specific Mortality for 195 Countries and Territories, 2016–2040. Lancet, 2018; 392: 2052–2090.
Gupta, S., Coca, S.G., Chan, L., et al. Faculty Recommendation for Renal Replacement Therapy in Critically Ill COVID-19 Patients. J. Am. Soc. Nephrol., 2021; 32: 161–176.
KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (KDIGO 2024). Kidney Int. Suppl., 2024.
Kunutsor, S.K., Laukkanen, J.A. Renal Complications in COVID-19: A Systematic Review and Meta-Analysis. Ann. Med., 2020; 52: 345–353.
Maldonado, D., Ray, J., Lin, H., et al. COVAN Leading to End-Stage Kidney Disease Despite Mild COVID-19 Symptoms. J. Investig. Med. High Impact Case Rep., 2022; 10: 23247096221093888.
Marra, F., Smolders, E.J., El-Sherif, O., et al. Recommendations for Dosing Repurposed Drugs for COVID-19 Treatment in Renal and Hepatic Impairment. Drugs R&D, 2020; 21: 9–27.
Nguyen, Y., Flahault, A., Chavarot, N., et al. Pre-exposure Prophylaxis with Tixagevimab and Cilgavimab (Evusheld) among 1112 Severely Immunocompromised Patients. Clin. Microbiol. Infect., 2022; 28: 1654.e1–1654.e4.
Puelles, V.G., Lütgehetmann, M., Lindenmeyer, M.T., et al. Multiorgan and Renal Tropism of SARS-CoV-2. N. Engl. J. Med., 2020.
Santerielo, D., Khairallah, P., Bomback, A.S., et al. Postmortem Kidney Pathology Findings in Patients with COVID-19. J. Am. Soc. Nephrol., 2020; 31: 2158–2167.
Seethapathy, R., Wang, Q., Zhao, S., et al. Impact of Remdesivir on Adverse Kidney Outcomes in Hospitalized Patients with COVID-19 and Kidney Impairment. PLoS ONE, 2023; 18: e0279765.
Su, H., Yang, M., Wang, C., et al. Histopathologic Analysis of Kidney Tissue from 26 Postmortem COVID-19 Patients in China. Kidney Int., 2020; 98: 219–227.
Thakare, S., Gandhi, C., Modi, T., et al. Safety of Remdesivir in Patients with Acute or Chronic Kidney Disease. Kidney Int. Rep., 2021; 6: 206–210.
Violetta, L., Kartasasmita, A.S., Amirullah Roesli, R.M., Rita, C. Pharmacological Treatment Options for COVID-19 in Renal Patients. Int. J. Nephrol., 2021; 2021: 4078713.
World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. Geneva: WHO, 2023.